Search Results
Year | ID | Type | Category | Title | Authors |
---|
2016 | NI03 | Poster | Neuroimaging and Neurophysiology |
Clippers: Case Presentation |
Carolina Tramontini, MD1, Juan Mora, MD1, Jorge Suárez, MD1 and Carlos Navas, MD2, (1)Diagnostic Imaging, Fundación Universitaria Sanitas, Bogota, Colombia, (2)FUNDACION UNIVERSITARIA SANITAS, BOGOTA, Colombia |
2016 | NI04 | Poster | Neuroimaging and Neurophysiology |
Spinal Cord Lesions on MRI : Nmo Spectrum Vs MS |
Carolina Tramontini, MD1, Juan Mora, MD1 and Carlos Navas, MD2, (1)Diagnostic Imaging, Fundación Universitaria Sanitas, Bogota, Colombia, (2)FUNDACION UNIVERSITARIA SANITAS, BOGOTA, Colombia |
2016 | NI05 | Poster | Neuroimaging and Neurophysiology |
Multiple Sclerosis, Magnetic Resonance Imaging, Signal-to-Noise Ratio, Signal Intensity |
Carolina Tramontini, MD1, Juan Mora, MD1 and Carlos Navas, MD2, (1)Diagnostic Imaging, Fundación Universitaria Sanitas, Bogota, Colombia, (2)FUNDACION UNIVERSITARIA SANITAS, BOGOTA, Colombia |
2016 | NI06 | Poster | Neuroimaging and Neurophysiology |
Volume of Subcortical Grey Matter Structures and Gait Outcomes in Multiple Sclerosis |
Elizabeth A Hubbard, MSc1, Nathan C Wetter, MD2, Bradley P Sutton, PhD2, Lara A Pilutti, PhD1 and Robert W Motl, PhD1, (1)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, (2)Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL |
2016 | NI07 | Poster | Neuroimaging and Neurophysiology |
Cervical Spinal Cord Diffusion Tensor Imaging and Gait Analysis in MS |
Jeffrey Gluckstein, BS1, Gautam Adusumilli, Undergraduate Student2, Samantha Lancia, MS2, Courtney Dula, MS2, Junqian Xu, PhD3, Joanne M Wagner, PT, PhD4 and Robert T Naismith, MD5, (1)Neurology, Washington University, Saint Louis, MO, (2)Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine in St. Louis, St. Louis, MO, (3)Radiology, Mount Sinai School of Medicine, New York, NY, (4)Department of Physical Therapy and Athletic Training, Saint Louis University, St. Louis, MO, (5)Neurology, Washington University School of Medicine, St Louis, MO |
2016 | NI08 | Poster | Neuroimaging and Neurophysiology |
Common Mistakes Made on MRI in MS |
Juan Mora, MD1, Jorge Suárez, MD1, Carolina Tramontini, MD1 and Carlos Navas, MD2, (1)Diagnostic Imaging, Fundación Universitaria Sanitas, Bogota, Colombia, (2)FUNDACION UNIVERSITARIA SANITAS, BOGOTA, Colombia |
2016 | NI09 | Poster | Neuroimaging and Neurophysiology |
Multiple Sclerosis, Fat-Saturated T2-Weighted MRI, FLAIR MRI, Agreement |
Juan Mora, MD1, Carolina Tramontini, MD1 and Carlos Navas, MD2, (1)Diagnostic Imaging, Fundación Universitaria Sanitas, Bogota, Colombia, (2)FUNDACION UNIVERSITARIA SANITAS, BOGOTA, Colombia |
2016 | NI10 | Poster | Neuroimaging and Neurophysiology |
Diffusion Weighted Imaging Changes in Multiple Sclerosis Patients |
Mirla Avila, MD, Sasikanth Gorantla, MD, Angel O Claudio, MD and John DeToledo, MD, Neurology, Texas Tech, Lubbock, TX |
2016 | NI11 | Poster | Neuroimaging and Neurophysiology |
The Evaluation of MRI Diffusion Values of Active Demyelinating Lesions in Multiple Sclerosis |
Mohammad Abdoli, MD1, Santanu Chakraborty, MD, MRCP2, Heather MacLean, MD, FRCPC1 and Mark S Freedman, MD3, (1)Neurology, University of Ottawa, Ottawa, ON, Canada, (2)Neuroradiology, University of Ottawa, Ottawa, ON, Canada, (3)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada |
2016 | NI12 | Poster | Neuroimaging and Neurophysiology |
The Relationship Between Multiple Sclerosis and Middle Cerebellar Peduncle Lesions: An Exploratory Study |
Olivia M Gutgsell, BS1, Luka Vlahovic, MD1 and Matthew McCoyd, MD2, (1)Loyola University Chicago Stritch School of Medicine, Maywood, IL, (2)Loyola University of Chicago MS Clinic, Maywood, IL |
2016 | NI13 | Poster | Neuroimaging and Neurophysiology |
Analysis of White Matter Tracts of Resting State Cognitive Networks in Multiple Sclerosis |
Rahil M Dharia, BSc1,2, Esmaeil Davoodi-Bojd, PhD1, Quan Jing, PhD1, Lian Li, PhD1 and Mirela Cerghet, MD, PhD1, (1)Neurology, Henry Ford Hospital, Detroit, MI, (2)School of Medicine, Wayne State University, Detroit, MI |
2016 | PO01 | Poster | Patient Reported Outcomes |
Gender Differences in Health Related Quality of Life in Multiple Sclerosis Patients with Increasing Disability |
Allison LaRussa, BA1, Alicia S Chua, M.S.2, Brian C Healy, PhD1, Fiona Stuart, BA1, Kaitlynne Leclaire, BA1, Riley Bove, MD1, Maria K Houtchens, MD1, Sandra Cook, RN1, Tanuja Chitnis, MD3, Howard L Weiner, MD1 and Bonnie I Glanz, PhD4, (1)Neurology, Brigham and Women’s Hospital, Brookline, MA, (2)Partners MS Center, Brigham and Women’s Hospital, Brookline, MA, (3)Massachusetts General Hospital for Children, Boston, MA, (4)Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Brookline, MA |
2016 | PO02 | Poster | Patient Reported Outcomes |
Impact of Multiple Sclerosis Disease Type on Productivity in a Propensity-Matched Cohort of Narcoms Participants |
Amber Salter, PhD, Division of Biostatistics, Washington University in St. Louis, St. Louis, MO, Nina Thomas, MPH, Genentech, Inc, South San Francisco, CA, Gary Cutter, PhD, University of Alabama at Birmingham, Birmingham, AL, Tuula Tyry, PhD, Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ and Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg, MB, Canada |
2016 | PO03 | Poster | Patient Reported Outcomes |
Using Patient Reported Outcomes to Evaluate MS Specialist Nursing in the UK |
Amy Bowen, RN, MA, Multiple Sclerosis Trust, Letchworth, United Kingdom of Great Britain and Northern Ireland |
2016 | PO04 | Poster | Patient Reported Outcomes |
Autoinjector Ease-of-Use in Patients with Multiple Sclerosis Treated with Interferon ß-1a Subcutaneously: Preliminary Data from REDEFINE |
Sibyl Wray, MD1, Barry A Singer, MD2, Brooke Hayward, SM, MBA3 and Choon Cha, MD3, (1)Hope Neurology Multiple Sclerosis Center, Knoxville, TN, (2)The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, (3)EMD Serono, Inc., Rockland, MA |
2016 | PO05 | Poster | Patient Reported Outcomes |
MS Self™, an Educational Application for People with Multiple Sclerosis (MS): Patient Experience in Recording MS-Related Symptoms and Daily Activities |
Cynthia B. Guerra, MBA1, Brandy Northcutt, _1, Richard Muser, _1, Michael Russo, _1, Joe McBride, _2 and Adrian L. Rabinowicz, MD1, (1)Acorda Therapeutics, Inc, Ardsley, NY, (2)Studio PMG, Irvine, NY |
2016 | PO06 | Poster | Patient Reported Outcomes |
A Phase IV Open-Label Study of Clinical Outcome Assessments to Facilitate Patient–HCP Interaction in MS: Study Design and Rationale |
Donald Barone, DO1, Mark Gudesblatt, MD2, Susan E Bennett, PT, DPT, EdD, NCS, MSCS3, Megan Weigel, DNP, ARNP-C, MSCN4, Amy Perrin Ross, APN, MSN, CNRN, MSCN5, Brooke Hayward, SM, MBA6 and Frederick Munschauer, MD6, (1)Rowan University, Stratford, NJ, (2)South Shore Neurologic Associates, Patchogue, NY, (3)State University of New York at Buffalo, Buffalo, NY, (4)Baptist Neurology Beaches Division, South Jacksonville Beach, FL, (5)Loyola University Chicago, Maywood, IL, (6)EMD Serono, Inc., Rockland, MA |
2016 | PO07 | Poster | Patient Reported Outcomes |
Perceptions of Multiple Sclerosis in 2015: A Public Disease-Awareness Survey |
Doug Taylor, BSc1, Nipa Patel, BA2 and Philip Sjostedt, BPharm2, (1)Institute for Evidence Based Medicine, New Hope, PA, (2)The Medicine Group, New Hope, PA |
2016 | PO08 | Poster | Patient Reported Outcomes |
Conjoint Analysis of Preferred Features of a Hypothetical First Dose Observation Program Among Patients and Neurologists before Fingolimod Initiation in Multiple Sclerosis |
Edward J. Fox, MD, PhD1, John Ko, Pharm.D, MS2, Paul Wicks, PhD3, Yujin Park, PharmD4, Pronabesh DasMahapatra, MD, MPH3, Kathryn Kendall, MBA3, Walter Hong, MD2, Erik Burton, MD2, Kathleen Hawker, MD2, Irina Kosoy, BBA5, Dimitri Liakhovitski, PhD5 and Vivian Herrera, DDS, MIA, MPH2, (1)Central Texas Neurology Consultants, Round Rock, TX, (2)Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)PatientsLikeMe Inc., Cambridge, MA, (4)Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, (5)North America, Gfk, New York, NY |
2016 | PO09 | Poster | Patient Reported Outcomes |
Treatment Satisfaction Across Injectable, Infusion, and Oral Disease-Modifying Therapies for Multiple Sclerosis |
Fiona Stuart, BA1, Alicia S Chua, M.S.2, Allison LaRussa, BA1, Kaitlynne Leclaire, BA1, Sandra Cook, RN1, Tanuja Chitnis, MD3, Howard L Weiner, MD1, Brian C Healy, PhD4 and Bonnie I Glanz, PhD5, (1)Neurology, Brigham and Women’s Hospital, Brookline, MA, (2)Partners MS Center, Brigham and Women’s Hospital, Brookline, MA, (3)Massachusetts General Hospital for Children, Boston, MA, (4)Biostatistics Center, Massachusetts General Hospital, Boston, MA, (5)Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Brookline, MA |
2016 | PO10 | Poster | Patient Reported Outcomes |
MS in US Minorities: Continuation of a Research Study Designed to Understand Educational Needs of Hispanic and African American Patients with MS |
Gregory D Salinas, PhD1, Brandon Coleman, BS1, Eleana Hardy, BA2, Jeffrey Smith, MS MBA2, Leslie Meltzer, PhD2 and Terrie Livingston, PharmD2, (1)CE Outcomes, LLC, Birmingham, AL, (2)Biogen, Cambridge, MA |
2016 | PO11 | Poster | Patient Reported Outcomes |
Real-World Patient Retention and Satisfaction on Fingolimod Versus Platform Injectable Disease-Modifying Therapies in Early RRMS: Results from PREFERMS |
Heidi Crayton, MD1, Brian Steingo, MD2, DeRen Huang, MD, PhD3, Xiangyi Meng, PhD4, Lesley Schofield, PhD4, Kristen Johnson, PhD4, Nadia Tenenbaum, MD4 and * on behalf of the PREFERMS investigators, **please delete**5, (1)MS Center of Greater Washington, Vienna, VA, (2)Sunrise Medical Group, Sunrise, FL, (3)Neurology and Neuroscience Associates, Akron, OH, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)**please delete**, **please delete**, NJ |
2016 | PO12 | Poster | Patient Reported Outcomes |
Development and Use of the iConquerMS Research Network for Patient-Centered Research |
Hollie Schmidt, MS1, Robert N. McBurney, PhD1, Deborah Backus, PT, PhD2, Laura Kolaczkowski, BA1, Sara Loud, MSEE, MBA1 and Revere P. Kinkel, MD3, (1)Accelerated Cure Project for MS, Waltham, MA, (2)Multiple Sclerosis Institute, Shepherd Center, Atlanta, GA, (3)University of California San Diego, San Diego, CA |
2016 | PO13 | Poster | Patient Reported Outcomes |
Treatment Patterns Associated with Relapsing-Remitting Multiple Sclerosis Patients on 1st-Line Injectable Disease Modifying Therapies |
Jacqueline Nicholas, MD, MPH1, John Ko, Pharm.D, MS2, Yujin Park, PharmD3, Prakash Navaratnam, Rph, MPH, PhD4, Howard Friedman, PhD4, Frank Ernst, Pharm.D, MS5, Erik Burton, MD2, Walter Hong, MD2 and Vivian Herrera, DDS, MIA, MPH2, (1)Neuroscience, Ohio Health, Columbus, OH, (2)US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, (4)DataMed Solutions LLC., Hilliard, OH, (5)Health Economics & Outcomes Research, Indegene TTM, Kennesaw, GA |
2016 | PO14 | Poster | Patient Reported Outcomes |
Gastrointestinal Symptoms in Early Dimethyl Fumarate Therapy |
John Foley, MD, Tamara Hoyt, MS, Cortnee Roman, NP, Angelene Christensen, BS and Ryan Metzger, PhD, Rocky Mountain MS Research Group, Salt Lake City, UT |
2016 | PO15 | Poster | Patient Reported Outcomes |
The Effect of Comorbid Allergies on the Physical and Psychosocial Outcomes of Multiple Sclerosis Patients – a Th1/Th2 Paradigm of Autoimmune Disease |
Joss Cohen, MD candidate1, Katelyn S. Kavak, MS2, Caila B Vaughn, MPH2,3,4, Robert Zivadinov, MD, PhD2,5, Jessica F Robb, MD2,6, Burk Jubelt, MD2,7, Lore Garten, MD2,8, Ilya Kister, MD2,9, Lauren Krupp, MD2,9, Malcolm Gottesman, MD2,10, Barbara E. Teter, PhD, MPH4 and Bianca Weinstock-Guttman, MD2,3,4, (1)Neurology, University at Buffalo Jacobs School of Medicine, Buffalo, NY, (2)New York State Multiple Sclerosis Consortium, Buffalo, NY, (3)Jacobs MS Center of Treatment and Research, Buffalo, NY, (4)Department of Neurology, University at Buffalo, Buffalo, NY, (5)Department of Neurology, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center, Buffalo, NY, (6)University of Rochester Medical Center, Rochester, NY, (7)SUNY Upstate Medical University, Syracuse, NY, (8)MS Center of Northeastern New York, Latham, NY, (9)NYU Langone Medical Center, New York, NY, (10)Winthrop Comprehensive MS Care Center, Mineola, NY |
2016 | PO16 | Poster | Patient Reported Outcomes |
Determining MS Relapses in Clinical Practice: How Do Clinicians Decide? |
Kelsey Zorn, BA1, Katherine J Kim, MPH2, Louis S. Matza, PHD2, Glenn Phillips, PhD3, Kitty S. Chan, PHD4, Sandra D. Cassard, ScD5, Katherine C Smith, PhD1 and Ellen Mowry, MD, MCR5, (1)Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (2)Evidera, Bethesda, MD, (3)Biogen, Cambridge, MA, (4)Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, (5)Neurology, Johns Hopkins School of Medicine, Baltimore, MD |
2016 | PO17 | Poster | Patient Reported Outcomes |
Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis after Suboptimal Response to Glatiramer Acetate: Respond 6-Month Interim Analysis |
Kiren Kresa-Reahl, MD1, Pavle Repovic, MD, PhD2, Derrick S Robertson, MD3, Macaulay Okwuokenye, DrPH4, Leslie Meltzer, PhD4 and Jason Mendoza, PhD4, (1)Providence Multiple Sclerosis Center, Portland, OR, (2)Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, (3)Neurology, University of South Florida, Tampa, FL, (4)Biogen, Cambridge, MA |
2016 | PO18 | Poster | Patient Reported Outcomes |
What Factors Influence Changes in MS Management? Comparing the Perspectives of Patients and Health Care Providers Using Nominal Group Technique |
Andrew J Solomon, MD1, Haiyan Qu, PhD, MHSA2, Vicky Springmann, MSc3, Carolina Ionete, MD, PhD4, Enrique Alvarez, MD5, Lori Pbert, PhD4, Carolyn Griffin, RN6, Brenda Tierman, RN7, Ashli Hopson, BA7, Christen Kutz, PA, PhD8, Idanis Idanis Berriosmorales, MD4, Glenn Phillips, PhD9 and Nananda F Col, MD, MPH, MPP, FACP7, (1)Neurological Sciences, University of Vermont College of Medicine, Burlington, VT, (2)Minority Health & Health Disparities Research Center; Health Services Administration, University of Alabama, Birmingham, Birmingham, AL, (3)Public Health Ontario, Toronto, ON, Canada, (4)University of Massachusetts Memorial Medical Center, Worcester, MA, (5)Neurology, University of Colorado, Aurora, CO, (6)Department of Neurology, University of Massachusetts Medical School, Worcester, MA, (7)Shared Decision Making Resources, Georgetown, ME, (8)Colorado Springs Neurological Associates, Colorado Springs, CO, (9)Biogen Idec Inc., Weston, MA, USA, Cambridge, MA |
2016 | PO19 | Poster | Patient Reported Outcomes |
Improvements in Patient-Reported Outcomes (PROs) with Teriflunomide: Results from the US Cohort of the Teri-PRO Phase 4 Study |
Patricia K Coyle, MD1, Chris LaGanke, MD2, Bhupendra Khatri, MD3, Keith R Edwards, MD4, Steve Cavalier, MD5, Pascal Rufi, MD6, Sandrine Brette, MSc7, Miqun Robinson, MD, PhD8, Matt Mandel, MD5 and Ralf Gold, MD9, (1)Stony Brook University, Stony Brook, NY, (2)North Central Neurology Associates, Cullman, AL, (3)The Regional MS Center, Center for Neurological Disorders, Wheaton Franciscan Health Care, Milwaukee, WI, (4)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (5)Genzyme, a Sanofi company, Cambridge, MA, (6)Genzyme, a Sanofi company, Chilly-Mazarin, France, (7)Lincoln, Boulogne-Billancourt, France, (8)Sanofi, Bridgewater, NJ, (9)St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany |
2016 | PO20 | Poster | Patient Reported Outcomes |
Integrated Mobile Health Platform – MS101.Me: Daily Patient Record of Symptoms, Medication Adherence, Sleep, and Activity to Support Outcome Assessment and Shared Decisions |
Robert L Knobler, MD, PhD, KIND Clinic, Knobler Institute of Neurologic Disease, Fort Washington, PA |
2016 | PO21 | Poster | Patient Reported Outcomes |
Factors Associated with Sexual Dysfunction in Patients with Multiple Sclerosis: An Exploratory Study |
Samantha Domingo, Psy.D.1, Lael A. Stone, M.D.2, Shauna Clement, PA-C2, Nicolas Thompson, M.S.3 and Amy Sullivan, Psy.D.4, (1)The Mellen Center for Multiple SclerosisTreatment and Research, Cleveland Clinic, Cleveland, OH, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, (3)Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, (4)The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH |
2016 | PO22 | Poster | Patient Reported Outcomes |
Patient-Reported Outcomes in Patients with Varying Clinical Disease Activity of Relapsing-Remitting Multiple Sclerosis in the DECIDE Study |
Wanda Castro-Borrero, MD1, Mariko Kita, MD2, Eva Havrdova, MD, PhD3, Bhupendra Khatri, MD4, Keith R Edwards, MD5, Bruce AC Cree, MD, PhD6, Shulian Shang, PhD1, Glenn Phillips, PhD1 and Ying Liu, PhD1, (1)Biogen, Cambridge, MA, (2)Virginia Mason Multiple Sclerosis Center, Seattle, WA, (3)Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, (4)The Regional MS Center, Center for Neurological Disorders, Wheaton Franciscan Health Care, Milwaukee, WI, (5)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (6)University of California San Francisco, San Francisco, CA |
2016 | PO23 | Poster | Patient Reported Outcomes |
Case Report: Use of Fingolimod in an Hispanic MS Pediatric Patient |
Eduardo R Estades, MD1, Angel Chinea, MD2, Yatzka G Hernandez Silvestrini, MD1, Ivonne Vicente, MD2 and Cristina Rubi, BS2, (1)Research/Clinic, San Juan MS Center, Guaynabo, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR |
2016 | QL01 | Poster | Quality of Life |
Analysis of Spirituality in Patients with Multiple Sclerosis |
Ana M Canzonieri, DRA, Mauricio O Bando Sr., Sr, Lucas F.R dos Santos Sr., student and Jean I Francisco, Sr, Research, ABEM . Brazilian Association Multiple Sclerosis, São Paulo, Brazil |
2016 | QL02 | Poster | Quality of Life |
Supporting the Children – Resources for Families Where One Parent Has MS |
Andrea Salmon, BAppSci(Occup Therapy), Services Innovation, Multiple Sclerosis Limited, Melbourne, Australia |
2016 | QL03 | Poster | Quality of Life |
Perceptions of and Experiences with the High Cost of MS Disease-Modifying Therapies |
Bari Talente, JD, National MS Society, Washington, DC |
2016 | QL04 | Poster | Quality of Life |
Pregnancy Decision-Making in Women with Multiple Sclerosis |
Caila B Vaughn, MPH1,2,3, Katelyn S. Kavak, MS1,2, Barbara E. Teter, PhD, MPH3, Patricia K Coyle, MD2,4, Keith R Edwards, MD, FAAN2,5, Karen Zakalik, MBA1, Muhammad Nadeem, MD3, Lana Zhovtis Ryerson, MD2,6, Allan Perel, MD2,7, Michael Lenihan, MD2,8, Robert Zivadinov, MD, PhD2,9, Lore Garten, MD2,10, Jessica F Robb, MD2,11, Burk Jubelt, MD2,12, Ilya Kister, MD2,6,13, Lauren Krupp, MD2,6, Malcolm Gottesman, MD2,14, Andrew Goodman, MD2,11 and Bianca Weinstock-Guttman, MD1,2,3, (1)Jacobs MS Center of Treatment and Research, Buffalo, NY, (2)New York State Multiple Sclerosis Consortium, Buffalo, NY, (3)Department of Neurology, University at Buffalo, Buffalo, NY, (4)Department of Neurology, Stony Brook University Medical Center, Stony Brook, NY, (5)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (6)NYU Langone Medical Center, New York, NY, (7)Comprehensive Multiple Sclerosis Center of Staten Island, Staten Island, NY, (8)Adirondack Neurology Associates, Glens Falls, NY, (9)Department of Neurology, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center, Buffalo, NY, (10)MS Center of Northeastern New York, Latham, NY, (11)Neurology, University of Rochester, Rochester, NY, (12)SUNY Upstate Medical University, Syracuse, NY, (13)Department of Neurology, New York University Medical Center, New York, NY, (14)Winthrop Comprehensive MS Care Center, Mineola, NY |
2016 | QL05 | Poster | Quality of Life |
Progression of MS Among an Aging New York State Population |
Aisha Bushra, MD1,2, Caila B Vaughn, MPH1,2,3, Katelyn S. Kavak, MS1,2,3, Katia Noyes, PhD, MPH4, Robert Zivadinov, MD, PhD2,5, Jessica F Robb, MD2,6, Burk Jubelt, MD7, Ilya Kister, MD2,8,9, Lauren Krupp, MD2,9, Malcolm Gottesman, MD2,10, Lore Garten, MD2,11 and Bianca Weinstock-Guttman, MD1,2,3, (1)Jacobs MS Center of Treatment and Research, Buffalo, NY, (2)New York State Multiple Sclerosis Consortium, Buffalo, NY, (3)Department of Neurology, University at Buffalo, Buffalo, NY, (4)University of Rochester School of Medicine, Rochester, NY, (5)Department of Neurology, State University of New York at Buffalo, Buffalo Neuroimaging Analysis Center, Buffalo, NY, (6)University of Rochester Medical Center, Rochester, NY, (7)SUNY Upstate Medical University, Syracuse, NY, (8)Department of Neurology, New York University Medical Center, New York, NY, (9)NYU Langone Medical Center, New York, NY, (10)Winthrop Comprehensive MS Care Center, Mineola, NY, (11)MS Center of Northeastern New York, Latham, NY |
2016 | QL06 | Poster | Quality of Life |
Increasing Disability Decreases Employment Levels in Patients with Multiple Sclerosis |
Tiffany M. Shih, Ph.D.1, Ning Wu, Ph.D.2, Craig Wakeford, M.A.3 and Darius N. Lakdawalla, Ph.D.1, (1)Precision Health Economics, Los Angeles, CA, (2)Global Health Economics and Outcomes Research, Biogen, Cambridge, MA, (3)Health Economics and Outcomes Research, Biogen, Cambridge, MA |